News | EP Mapping and Imaging Systems | October 29, 2018

First Carto Vizigo Bi-Directional Guiding Sheath Employed on West Coast

Sheath can be visualized on Carto 3 system during catheter ablation to reduce dependence on fluoroscopy

First Carto Vizigo Bi-Directional Guiding Sheath Employed on West Coast

October 29, 2018 — Good Samaritan Hospital recently became the first hospital on the West Coast to utilize the Carto Vizigo bi-directional guiding sheath. The sheath can be visualized on the Carto 3 System during a catheter ablation procedure, helping electrophysiologists reduce dependency on fluoroscopy.

A sheath is an introducer routinely used by physicians to facilitate catheter access, stability and tissue contact when targeting sites for catheter ablation to treat arrhythmias. Electrophysiologists rely on fluoroscopy to identify the location of the sheath, therefore requiring use of lead to protect themselves from radiation during the procedure.

According to Ivan Ho, M.D., electrophysiologist practicing at Good Samaritan Hospital and the first to use the technology on the West Coast, the long deflectable sheath has become a major step forward in achieving catheter stability and appropriate radiofrequency energy delivery in complex left-sided arrhythmia ablations. "One of the limitations has been the need of periodic fluoroscopic imaging of the sheath's relative position with the catheter to optimize contact with endocardial surface and ensure safety due to the relatively stiff shaft of these sheaths," said Ho.  The Vizigo allows the direction of the sheath and its relationship with the catheter to be visualized accurately on a 3-D mapping system, minimizing the use of fluoroscopy and overall procedure time.

This new technology is incorporated easily into the physicians' workflow, designed to enhance efficiency during mapping and positioning of the ablation catheter. The smooth tip-to-dilator transition promotes ease of entry into the left atrium during transseptal access, while deflections of 180 degrees in both directions mean increased steerability, which may improve access to hard-to-reach sites.

For more information: www.biosensewebster.com


Related Content

News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Subscribe Now